A compound of Formula Ii, Ij, Il or Im: or stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, wherein: R 1 is selected from Br, Cl, I, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, -NR 3 R 4, and -OR 5; R 2 is selected from H, F, Cl, C 1 -C 6 alkyl, and -O(C 1 -C 6 alkyl); R 3 is selected from H, and C 1 -C 6 alkyl; R 4 is selected from H, C 1 -C 6 alkyl, C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; or R 3 and R 4 form a 4-membered, 5-membered or 6-membered heterocyclyl ring; R 5 is selected from C 1 -C 6 alkyl, C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; A is selected from C 6 -C 20 aryl, -(C 6 -C 20 aryl)-(C 6 -C 20 aryl), -(C 6 -C 20 aryl)-(C 1 -C 20 heteroaryl), -(C 6 -C 20 aryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 1 -C 20 heteroaryl), C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; and where alkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH 3, -CH 2 CH 3, -CH(CH 3) 2, C(CH 3) 3, -CH 2 CH(CH 3) 2, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -C(CH 3) 2 OH, -CH CH(CH 3) 2, -C(CH 3) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3, -CH 2 OP 2, -CH 2 F, -CHF 2, -CH 2 NH 2, -CH 2 NHSO 2 CH 3, -CH 2 NHCH 3, -CH 2 N(CH 3) 2, -CF 3, -CH 2 CF 3, -CH 2 CHF 2, -CH(CH 3)CN, -C(CH 3) 2 CN, -CH 2 CN, -CO 2 H, -COCH 3, -CO 2 CH 3, -CO 2 C(CH 3) 3, -COCH CH 3, -CONH 2, -CONHCH 3, -CONHCH 2 CH 3, -CONHCH(CH 3) 2, -CON(CH 3) 2, -C(CH 3) 2 CONH 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHCOCH 3, -N(CH 3)COCH 3, -NHS 2 CH 3, -N(CH 3)C(CH 3) 2 CONH 2, -N(CH 3)CH 2 CH 2 S 2 CH 3, -NO 2, =O, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OCH 3, -OCH 2 CH 2 OH, -OCH 2 CH 2 N(CH 3) 2, -OP 2, -S 2 N(CH 3) 2, -SCH 3, -S 2 CH 3, -S 3 H, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, cyclopentyl, tetrahydrofuranyl, morpholinyl, piperidyl, piperazinyl, and tetrahydropyranyl. R 1 is selected from Br, Cl, I, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, -NR 3 R 4, and -OR 5; R 2 is selected from H, F, Cl, C 1 -C 6 alkyl, and -O(C 1 -C 6 alkyl); R 3 is selected from H, and C 1 -C 6 alkyl; R 4 is selected from H, C 1 -C 6 alkyl, C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; or R 3 and R 4 form a 4-membered, 5-membered or 6-membered heterocyclyl ring; R 5 is selected from C 1 -C 6 alkyl, C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; A is selected from C 6 -C 20 aryl, -(C 6 -C 20 aryl)-(C 6 -C 20 aryl), -(C 6 -C 20 aryl)-(C 1 -C 20 heteroaryl), -(C 6 -C 20 aryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 1 -C 20 heteroaryl), C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; and where alkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH 3, -CH 2 CH 3, -CH(CH 3) 2, C(CH 3) 3, -CH 2 CH(CH 3) 2, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -C(CH 3) 2 OH, -CH CH(CH 3) 2, -C(CH 3) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3, -CH 2 OP 2, -CH 2 F, -CHF 2, -CH 2 NH 2, -CH 2 NHSO 2 CH 3, -CH 2 NHCH 3, -CH 2 N(CH 3) 2, -CF 3, -CH 2 CF 3, -CH 2 CHF 2, -CH(CH 3)CN, -C(CH 3) 2 CN, -CH 2 CN, -CO 2 H, -COCH 3, -CO 2 CH 3, -CO 2 C(CH 3) 3, -COCH CH 3, -CONH 2, -CONHCH 3, -CONHCH 2 CH 3, -CONHCH(CH 3) 2, -CON(CH 3) 2, -C(CH 3) 2 CONH 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHCOCH 3, -N(CH 3)COCH 3, -NHS 2 CH 3, -N(CH 3)C(CH 3) 2 CONH 2, -N(CH 3)CH 2 CH 2 S 2 CH 3, -NO 2, =O, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OCH 3, -OCH 2 CH 2 OH, -OCH 2 CH 2 N(CH 3) 2, -OP 2, -S 2 N(CH 3) 2, -SCH 3, -S 2 CH 3, -S 3 H, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, cyclopentyl, tetrahydrofuranyl, morpholinyl, piperidyl, piperazinyl, and tetrahydropyranyl.